U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Science & Research
  3. FDA Technology Transfer Program
  4. Licensing and Collaboration Opportunities
  5. A Novel Solid Support for Efficient Reduction of Process-Related Impurities in Synthetic Nucleic Acid Sequences
  1. Licensing and Collaboration Opportunities

A Novel Solid Support for Efficient Reduction of Process-Related Impurities in Synthetic Nucleic Acid Sequences

Download the Abstract (PDF - 115KB)

Technology Summary

The purity of synthetic nucleic acid sequences is essential to produce safe and efficacious nucleic acid-based drugs intended for antisense or RNA interference therapies. The use of antisense DNA (asDNA) sequences or small interfering RNA (SiRNA) duplexes have been demonstrated to be highly potent at silencing the expression of disease-causing proteins in vitro. However, the clinical applications to treat human diseases have been hindered by a number of fundamental issues including: (i) instability in biological media; (ii) poor delivery to target cells; (iii) poor uptake by target cells; and (iv) dose related toxicities (severe thrombocytopenic and/or peripheral neuropathy). One of the causes for these issues is the contamination with process-related impurities which consist of partially protected and/or 5’-uncapped DNA/RNA sequences that lead to the production of unwanted products.

To address this issue, FDA investigators have developed an improved solid support system that reduces impurities during the production of synthetic nucleic acid sequences. The solid support system consists of a 3-hydroxypropylated controlled-pore glass (CPG) support that has been prepared and functionalized with multiple hexaethylene spacers. The key difference in the CPG support is the transfer of the attachment site of the leader nucleoside further from the core of the solid support. This action facilitates the diffusion of the reagents and solvents to the lead nucleoside of the DNA/RNA sequence. Proof-of-concept studies show a reduction of process-related impurities in the nucleic sequences to an extent of <50%, when compared to that of the current commercially available, state-of-the-art long-chain alkylamine controlled pore glass (LCAA-CPG) supports. 

Potential Commercial Applications Competitive Advantages
  • Purification of synthetic nucleic acid sequences
  • Attachment site of the leader nucleoside moved to allow increased diffusion of reagents and solvents
  • Reduction in contaminants during solid-phase synthesis
     

Development Stage: Proof-of-concept system

Inventors: Serge Beaucage, Andrezej Grajkowski

Publication:

Grajkowski, A., et. al. An Improved PEG-Linked Solid Support for Minimizing Process-Related Impurities During Solid-Phase Synthesis of DNA and RNA Sequences. Curr Protoc. 2021 May;1(5):e108. PMID: 33945676

Intellectual Property:

U.S. provisional application 63/275,251 was filed November 3, 2021

PCT application PCT/US2022/078969 was filed October 31, 2022

Product Area:  CPG support, nucleic acid-based drugs, solid-phase DNA/RNA synthesis

FDA Reference No: E-2020-015

Licensing Contact:
FDA Technology Transfer Program
Email: FDAInventionlicensing@fda.hhs.gov 

Back to Top